Home Cart Sign in  
Chemical Structure| 199807-35-7 Chemical Structure| 199807-35-7

Structure of Cilengitide TFA
CAS No.: 199807-35-7

Chemical Structure| 199807-35-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptors, with IC50 values of 4 nM and 79 nM, respectively.

Synonyms: NSC 707544; EMD 121974; EMD 121974 TFA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cilengitide TFA

CAS No. :199807-35-7
Formula : C29H41F3N8O9
M.W : 702.68
SMILES Code : O=C(O)C(F)(F)F.O=C(O)C[C@@H](C(N[C@H](CC1=CC=CC=C1)C(N(C)[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(NC2)=O)=O)=O)=O)NC2=O
Synonyms :
NSC 707544; EMD 121974; EMD 121974 TFA
MDL No. :MFCD22665738
InChI Key :WHJCSACXAPYNTG-LOPTWHKWSA-N
Pubchem ID :129626550

Safety of Cilengitide TFA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cilengitide TFA

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • Integrin

    αvβ5 receptor, IC50:79 nM

    αvβ3 receptor, IC50:4.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 2 nM 24 h To evaluate the promoting effect of Cilengitide on HUVEC migration. The results showed that MC-T-DOX significantly increased the migration area of HUVECs, indicating that it promoted endothelial cell migration by releasing Cilengitide through MT1-MMP activation. Adv Sci (Weinh). 2020 Jul 10;7(17):1902746.
HUVECs 2 nM 8 h To evaluate the effect of Cilengitide on HUVEC tube formation. The results showed that MC-T-DOX significantly increased the number and length of tube-like structures, indicating that it promoted angiogenesis by releasing Cilengitide through MT1-MMP activation. Adv Sci (Weinh). 2020 Jul 10;7(17):1902746.
U87ΔEGFR cells 1.0 μM 16 h To study the effect of Cilengitide on gene expression in U87ΔEGFR cells, results showed changes in gene expression after Cilengitide treatment. Transl Oncol. 2014 Apr;7(2):292-302.e1.
MRC-5 cells 0.5 μM To investigate the inhibitory effect of Cilengitide on TGF-β1 activation in MRC-5 cells, results showed that Cilengitide inhibited TGF-β1 activation and its downstream signaling pathway. Clin Transl Med. 2024 Jan;14(1):e1546.
HSC3 cells 10 μM 15 min Inhibit the interaction between β5-integrin and the extracellular matrix, preventing FCL formation Nat Commun. 2022 Feb 16;13(1):905.
A2780 ovarian cancer cells 1 μM 20 min Promoted α5β1 integrin recycling, increased coprecipitation of RCP with α5β1, and drove tumor cell migration into three-dimensional matrices J Cell Biol. 2008 Oct 6;183(1):143-55.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Hypoperfused pancreatic cancer mouse model Intravenous injection 8.5 nM/kg Every 4 days for three cycles To evaluate the anti-angiogenic and anti-tumor effects of MC-T-DOX in a pancreatic cancer mouse model. The results showed that MC-T-DOX significantly increased tumor vascular density and the percentage of functional vessels, and improved tumor blood perfusion, resulting in significant tumor growth inhibition. Adv Sci (Weinh). 2020 Jul 10;7(17):1902746.
Nude mice and rats U87ΔEGFR brain tumor model Intraperitoneal injection 10 mg/kg Three times per week for 13 days To study the effect of Cilengitide in combination with Bevacizumab on glioma invasiveness, results showed that combination therapy significantly reduced the depth of tumor invasion. Transl Oncol. 2014 Apr;7(2):292-302.e1.
BALB/c nude mice Patient-derived xenograft (PDX) models Intratumor injection 10 mg/kg Once a week, 4 weeks Combination treatment with EMD and bevacizumab significantly inhibited tumor growth and decreased the number of VM channels and microvessels Mol Oncol. 2021 Dec;15(12):3447-3467.
Mice Radiation-induced pulmonary fibrosis model Intraperitoneal injection 15 or 75 mg/kg Once daily for 8 weeks To investigate the protective effect of Cilengitide on radiation-induced pulmonary fibrosis, results showed that Cilengitide significantly attenuated lung fibrosis and improved survival in mice. Clin Transl Med. 2024 Jan;14(1):e1546.
BALB/c nude mice HepG2 tumor model Intravenous injection 100 μg Single dose, lasting 30 minutes Used to block integrin αvβ3 receptors and validate the targeting of nanodots. Results showed significantly reduced tumor fluorescence signal in the blocking group, indicating that Cilengitide effectively inhibited the targeted accumulation of nanodots. Theranostics. 2019 Feb 12;9(5):1264-1279
Mice Liver fibrosis model Intraperitoneal injection 30 mg/kg Once daily for 3 weeks Cilengitide treatment significantly reduced liver fibrosis indicators in Ecm1Δhep mice, including serum ALT and AST activities, inflammatory damage, and collagen deposition. Redox Biol. 2024 Feb;69:103029.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.42mL

0.28mL

0.14mL

7.12mL

1.42mL

0.71mL

14.23mL

2.85mL

1.42mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories